Table 5.
IPDASi (probabilities) and development process ratings for tools
| |
IPDASi (Probabilities) items [12] |
Development process items |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 n (%) | 2 n (%) | 3 n (%) | 4 n (%) | 5 n (%) | 6 n (%) | 7 n (%) | 8 n (%) | Median (IQR) probabilities total | 1 n (%) | 2 n (%) | 3 n (%) | 4 n (%) | 5 n (%) |
6 n (%) |
|
| RCT |
5 (100) |
5 (100) |
5 (100) |
2 (40) |
2 (40) |
1 (20) |
4 (80) |
5 (100) |
5 (3) |
3 (60) |
1 (20) |
0 (0) |
1 (20) |
1 (20) |
0 (0) |
| PIT |
17 (100) |
17 (100) |
13 (77) |
6 (36) |
2 (12) |
1 (6) |
6 (36) |
3 (18) |
4 (1.5) |
8 (47) |
1 (6) |
0 (0) |
2 (12) |
3 (18) |
0 (0) |
| BDA |
2 (67) |
2 (67) |
0 (0) |
2 (67) |
2 (67) |
1 (33) |
1 (33) |
0 (0) |
4 (0) |
3 (100) |
1 (33) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
| SI |
1 (100) |
1 (100) |
1 (100) |
0 (0) |
1 (100) |
0 (0) |
0 (0) |
0 (0) |
4 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
| Overall | 25 (96) | 25 (96) | 19 (73) | 10 (39) | 7 (27) | 3 (12) | 11 (42) | 8 (31) | 4 (2) | 14 (54) | 3 (12) | 0 (0) | 3 (12) | 4 (15) | 0 (0) |
RCT = Risk communication tool PIT = Patient information tool BDA = Brief decision aid SI = Standardised information.
IPDASi (Probabilities) items: [12].
1 = provides information about outcome probabilities (OPs) associated with the options; 2 = specifies defined group (reference class) of patients for which the OPs apply; 3 = specifies the event rates for OPs (in natural frequencies); 4 = specifies time period over which the OPs apply; 5 = allows the user to compare OPs across options using the same denominator and time period; 6 = provides information about the levels of uncertainty around event/OPs; 7 = provides more than one way of viewing the probabilities; 8 = provides balanced information about event or OPs to limit framing biases.
Development process items:
1 = evidence that developers have considered best available evidence; 2 = intervention based on an established theory/body of evidence; 3 = elicitation study on risk/benefit information required by patients/families or clinicians; 4 = tool subjected to ‘testing’ in patients and families or clinicians; 5 = development of tool guided by steering group; 5 = tool subjected to exploratory trial.